Interleukin Related
IL
Interleukins are a group of cytokines (secreted proteins and signaling molecules) that were first seen to be expressed by white blood cells (leukocytes). The function of the immune system depends in a large part on interleukins, and rare deficiencies of a number of them have been described, all featuring autoimmune diseases or immune deficiency. The majority of interleukins are synthesized by helper CD4 T lymphocytes, as well as through monocytes, macrophages, and endothelial cells. They promote the development and differentiation of T and B lymphocytes, and hematopoietic cells. Interleukin receptors on astrocytes in the hippocampus are also known to be involved in the development of spatial memories in mice.
Interleukin Related Isoform Specific Products
-
Interleukin Related
(949)
View all products
-
IL-1
(483)
View all products
-
IL-2
(116)
View all products
-
IL-3
(8)
View all products
-
IL-4
(89)
View all products
-
IL-5
(34)
View all products
-
IL-6
(506)
View all products
-
IL-8
(103)
View all products
-
IL-10
(95)
View all products
-
IL-12
(39)
View all products
-
IL-13
(56)
View all products
-
IL-15
(10)
View all products
-
IL-17
(107)
View all products
-
IL-23
(38)
View all products
-
IL-7
(15)
View all products
-
IL-33
(5)
View all products
-
IL-22
(11)
View all products
-
IL-18
(23)
View all products
All Product Categories
-
Interleukin Related Inhibitors
(1594)
View all products
-
Interleukin Related Agonists
(15)
View all products
-
Interleukin Related Antagonists
(33)
View all products
-
Interleukin Related Activators
(166)
View all products
-
Interleukin Related Modulators
(101)
View all products
-
Interleukin Related Chemicals
(2)
View all products
-
Interleukin Related Inducers
(62)
View all products
-
Interleukin Related Degraders
(2)
View all products
-
Interleukin Related Controls
(2)
View all products
-
Interleukin Related Ligands
(10)
View all products
-
IL-4 Proteins
(26)
View all products
-
IL-12 Proteins
(39)
View all products
-
IL-17 Proteins
(71)
View all products
-
IL-8/CXCL8 Proteins
(16)
View all products
-
Multi-CSF/IL-3 Proteins
(18)
View all products
-
IL-1 Proteins
(43)
View all products
-
IL-2 Proteins
(22)
View all products
-
IL-5 Proteins
(20)
View all products
-
IL-6 Proteins
(24)
View all products
-
IL-10 Proteins
(16)
View all products
-
IL-13 Proteins
(19)
View all products
-
IL-15 Proteins
(18)
View all products
-
IL-23 Proteins
(22)
View all products
-
Interleukin Related Related Products (2249)
Related Products (2249)
-
Recombinant Proteins (352)
-
Antibodies (36)
-
Interleukin Related Isoform Comparison
-
NCGC-023
0 ImagesCat. No.: HY-187678CAS No.: 3024011-79-5NCGC-023 is a LATS1/2 inhibitor. NCGC-023 selectively inhibits LATS1/2, an upstream regulator of Yap in the Hippo signaling pathway, increases the expression of active Yap protein, activates Yap-dependent signaling pathways, triggers non-Yap-dependent metallothionein-mediated heavy metal responses, and upregulates IL-33-related regenerative responses. NCGC-023 can be used in studies related to gastrointestinal acute radiation syndrome (GI-ARS).
-
Anti-inflammatory agent 64
0 ImagesCat. No.: HY-155405CAS No.: 3016401-76-3Anti-inflammatory agent 64 (compound 4b) inhibits the secretion of IL-6 and TNF-α. Anti-inflammatory agent 64 has antioxidant and anti-inflammatory activity in vitro and in vivo. Anti-inflammatory agent 64 can effectively reduce paw edema .
-
NLRP3-IN-76
0 ImagesCat. No.: HY-170218NLRP3-IN-76 is an orally active NLRP3 inhibitor. NLRP3-IN-76 inhibits the production of NO, and the mRNA levels of proinflammatory cytokines (iNOS, IL-6, IL-1β and TNFα). NLRP3-IN-76 shows anti-inflammatory effects by inhibiting the activation of the NLRP3 inflammasome and NF-κB signaling pathway. NLRP3-IN-76 ameliorates DSS (HY-116282C)-induced colitis and can be used for research of inflammatory bowel diseases (IBD).
-
DG013A
0 ImagesCat. No.: HY-139907CAS No.: 2007955-07-7DG013A is a zinc-dependent M1-aminopeptidase inhibitor that exhibits inhibitory activity against ERAP1 (IC50 = 33 nM) and ERAP2 (IC50 = 11 nM). DG013A enhances SRHFLAFSFR epitope presentation, rescues GSW11 peptide neoantigen presentation, reduces SIINFEKL presentation, modulates the immunopeptidome, decreases HLA-B27 free heavy chain expression, and reduces IL-17A secretion. DG013A exhibits antiproliferative activity. DG013A can be used for research on autoimmune diseases and melanoma.
-
Akt/NF-κB/MAPK-IN-1
0 ImagesCat. No.: HY-149496CAS No.: 2994215-72-2Akt/NF-κB/MAPK-IN-1 (compound 2m) is a potent and orally active inhibitor against NO (IC50=7.70 μM) with no significant toxicity. Akt/NF-κB/MAPK-IN-1 shows anti-inflammatory activity by inhibiting Akt/NF-κB and MAPK signaling pathways.
-
cyclo-Cannabigerol
0 ImagesCat. No.: HY-172540Synonyms: cyclo-CBGcyclo-Cannabigerol (cyclo-CBG) is the major metabolite of Cannabigerol generated by cytochrome P450. Cyclo-Cannabigerol has weak anti-inflammatory activity.
-
Relaxin H3 (human)
0 ImagesCat. No.: HY-P4890CAS No.: 1158181-62-4Relaxin H3 (human) is a relaxin peptide with anti-inflammatory, anti-apoptotic, anti-pyroptotic, anti-migratory, protective and anti-fibrotic activities. Relaxin H3 (human) acts on RXFP1 to generate cAMP and reduce the levels of ATP and ROS. Relaxin H3 (human) inhibits renal inflammatory pyroptosis (pyroptosis), NLRP3 inflammasome activation, caspase-1 activation, IL-1β/IL-18 secretion, collagen synthesis, TGF-β1 signaling pathway, Smad2 phosphorylation, myofibroblast differentiation, TIMP expression, and HRMEC migration. Relaxin H3 (human) activates AMPK, upregulates MFN2 expression, improves mitochondrial quality control and membrane potential, inhibits apoptosis (apoptosis) and pyroptosis, restores retinal ultrastructure, and reverses excessive left ventricular collagen expression. Relaxin H3 (human) can be used in studies related to kidney stones, nephrocalcinosis, diabetic cardiomyopathy, fibrotic cardiomyopathy, and diabetic retinopathy.
-
Anti-IL-34 Antibody
0 ImagesCat. No.: HY-P992249
-
CLP-d2
0 ImagesCat. No.: HY-P11617CLP-d2 is a multi-target anti-inflammatory agent, osteoclastogenesis inhibitor and immunomodulator with superior pharmacokinetic properties to Daptomycin (HY-B0108) and good safety profiles. CLP-d2 inhibits the NF-κB and MAPK signaling pathways by reducing the expression levels of c-Fos and NFATc1, and decreasing the phosphorylation levels of IκBα, p65, ERK and JNK, thereby reducing the secretion of pro-inflammatory cytokines such as IL-6, TNF-α and IL-1β to exert anti-inflammatory activity. CLP-d2 inhibits intra-articular osteoclastogenesis in mice, alleviates bone erosion and joint swelling, reduces synovial hyperplasia and inflammatory cell infiltration, and decreases serum rheumatoid factor (RF) levels. CLP-d2 is applicable to related research on rheumatoid arthritis.
-
LY2189102
0 ImagesCat. No.: HY-P991269LY2189102 is a humanized monoclonal antibody inhibitor targeting interleukin-1β (IL-1β). LY2189102 is promising for research of type 2 diabetes.
-
Keap1-Nrf2-IN-25
0 ImagesCat. No.: HY-168922CAS No.: 3100306-80-4Keap1-Nrf2-IN-25 (Compound 19) is a potent Keap1-Nrf2 inhibitor (IC50 of 0.55 μM) with Keap1 binding affinity (Kd of 0.50 μM). Keap1-Nrf2-IN-25 activates Nrf2, reduces ROS and pro-inflammatory cytokines (IL-1β, IL-6). Keap1-Nrf2-IN-25 exerts protective effects against DSS (HY-116282)-induced colitis.
-
TT-301
0 ImagesCat. No.: HY-111203CAS No.: 886208-76-0Synonyms: MW189; MW01-6-189WHTT-301 is a small-molecule immunomodulator capable of penetrating the blood-brain barrier. TT-301 exerts neuroprotective effects by binding to IL-1β, downregulating STAT3 expression, and modulating the JAK-STAT signaling pathway, thereby inhibiting microglial activation and the release of proinflammatory mediators, and alleviating neuroinflammation and brain edema. TT-301 is used in research on traumatic brain injury, intracerebral hemorrhage, subarachnoid hemorrhage, muscle wasting and atrophy, and periodontal disease.
-
NLRP3-IN-75
0 ImagesCat. No.: HY-170233NLRP3-IN-75 is an orally active NLRP3 inhibitor. NLRP3-IN-75 suppresses IL-1β secretion (IC50 = 23 nM). NLRP3-IN-75 selectively inhibits NLRP3 activation by disrupting inflammasome assembly without affecting NLRC4 or AIM2 inflammasomes. NLRP3-IN-75 exhibits superior efficacy in acute peritonitis, diabetic kidney disease and IBD models.
-
Kansuinine B
0 ImagesKansuinine B is a natural diterpenoid compound with anti-inflammatory, anti-cancer and anti-viral activities, which can be isolated from the roots of Euphorbia kansui. Kansuinine B induces sustained ERK1/2 activation, inhibits IL-6-induced Stat3 activation and tyrosine phosphorylation, and enhances serine phosphorylation of Stat3. Kansuinine B negatively regulates the IL-6 signaling pathway by upregulating the expression of SOCS-3. Kansuinine B promotes the proliferation of mouse splenic lymphocytes in vitro and stimulates rat peritoneal macrophages to produce NO. Kansuinine B can be used in studies related to liver cancer and COVID-19.
-
Balsalazide-d3
0 ImagesCat. No.: HY-B0667SCAS No.: 1246834-21-8Balsalazide-d3 is the deuterium labeled Balsalazide (HY-B0667). Balsalazide is a prodrug of amino salicylic acid that releases mesalamine (HY-15027) in the colon, offering various anti-inflammatory effects in areas of colitis, and it also exerts related anticancer effects by regulating the IL-6/STAT3 pathway.
-
IMG-008
0 ImagesCat. No.: HY-P992384Purity: 99.50%IMG-008 is a fully human antagonistic antibody targeting IL-36R, acting as a high-affinity IL-36R inhibitor (Kd = 6.23 pM). IMG-008 competitively blocks the pro-inflammatory signaling pathway mediated by human IL-36R, inhibiting receptor activation and the production of inflammatory cytokines. IMG-008 suppresses Imiquimod (HY-B0180)-induced skin inflammation in humanized mice, and Fc modification increases its serum exposure and prolongs its half-life. IMG-008 can be used in studies related to IL-36R-mediated inflammatory diseases such as psoriasis.
-
BMAP-27
0 ImagesCat. No.: HY-P5286CAS No.: 184870-30-2BMAP-27 is a cationic amphipathic α-helical antimicrobial peptide with anticancer activity. BMAP-27 disrupts the integrity and permeability of cell membranes, leading to the leakage of intracellular DNA, proteins and alkaline phosphatase. BMAP-27 increases intracellular ROS levels and reduces plasma endotoxin and TNF-α concentrations. BMAP-27 can be used in studies related to Salmonella infection, breast cancer, lung cancer and obstructive jaundice.
-
Itaconic acid prodrug-1
0 ImagesCat. No.: HY-172148CAS No.: 2641132-66-1Itaconic acid prodrug-1 (Compound P2) is an orally active prodrug of Itaconic acid (HY-Y0520) that efficiently delivers the active ingredient Itaconic acid to skin tissue following oral administration. Itaconic acid prodrug-1 possesses immunomodulatory properties, significantly inhibiting Poly(I:C)/IFNγ-induced inflammatory cytokines in human epidermal keratinocytes. Itaconic acid prodrug-1 can be utilized for the research of alopecia areata and other inflammatory skin diseases.
-
(±)-Methotrexate-13C,d3 disodium
0 ImagesCat. No.: HY-121151S2Synonyms: (±)-Amethopterin-13C,d3 disodium; (±)-CL14377-13C,d3 disodium; (±)-WR19039-13C,d3 disodium(±)-Methotrexate-13C,d3 disodium ((±)-Amethopterin-13C,d3 disodium; (±)-CL14377-13C,d3 disodium; (±)-WR19039-13C,d3 disodium) is the deuterated, 13C-labeled (±)-Methotrexate (HY-121151). (±)-Methotrexate is the racemate of Methotrexate (HY-14519). Methotrexate is an orally active antifolate (Antifolate). Methotrexate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
-
Deucravacitinib-13C,d3
0 ImagesCat. No.: HY-166594SDeucravacitinib-13C,d3 is the 13C- and deuterium labeled Deucravacitinib. Deucravacitinib (BMS-986165) is a highly selective, orally bioavailable allosteric TYK2 inhibitor for the treatment of autoimmune diseases, which selectively binds to TYK2 pseudokinase (JH2) domain (IC50=1.0 nM) and blocks receptor-mediated Tyk2 activation by stabilizing the regulatory JH2 domain. Deucravacitinib inhibits IL-12/23 and type I IFN pathways. Deucravacitinib, the FDA's world first de novo deuterium, is available for study in moderate to severe plaque psoriasis.
